These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16753284)

  • 41. Medical risk in patients with bipolar disorder and schizophrenia.
    Newcomer JW
    J Clin Psychiatry; 2006 Nov; 67(11):e16. PubMed ID: 17201046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study.
    Liao CH; Chang CS; Wei WC; Chang SN; Liao CC; Lane HY; Sung FC
    Schizophr Res; 2011 Mar; 126(1-3):110-6. PubMed ID: 21216567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antipsychotic medications: metabolic and cardiovascular risk.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antipsychotic drugs and risk of type 2 diabetes: an evidence-based approach.
    Bellantuono C; Tentoni L; Donda P
    Hum Psychopharmacol; 2004 Dec; 19(8):549-58. PubMed ID: 15378663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes.
    Leslie DL; Rosenheck RA
    Psychiatr Serv; 2005 Jul; 56(7):803-9. PubMed ID: 16020811
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Data on diabetes from the French cohort study in schizophrenia.
    Philippe A; Vaiva G; Casadebaig F
    Eur Psychiatry; 2005 Dec; 20 Suppl 4():S340-4. PubMed ID: 16459248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.
    Goff DC; Sullivan LM; McEvoy JP; Meyer JM; Nasrallah HA; Daumit GL; Lamberti S; D'Agostino RB; Stroup TS; Davis S; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):45-53. PubMed ID: 16198088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between antipsychotic drugs and diabetes.
    Holt RI; Peveler RC
    Diabetes Obes Metab; 2006 Mar; 8(2):125-35. PubMed ID: 16448516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment.
    Zhai D; Cui T; Xu Y; Feng Y; Wang X; Yang Y; Li S; Zhou D; Dong G; Zhao Y; Yang Y; Zhang R
    Schizophr Res; 2017 Jan; 179():41-49. PubMed ID: 27613506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IAP National Task Force for Childhood Prevention of Adult Diseases: insulin resistance and Type 2 diabetes mellitus in childhood.
    Bhatia V;
    Indian Pediatr; 2004 May; 41(5):443-57. PubMed ID: 15181295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Schizophrenia, the metabolic syndrome and diabetes.
    Holt RI; Peveler RC; Byrne CD
    Diabet Med; 2004 Jun; 21(6):515-23. PubMed ID: 15154933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atypical antipsychotics and the risk of diabetes in an elderly population in long-term care: a retrospective nursing home chart review study.
    Albert SG; Grossberg GT; Thaipisuttikul PJ; Scouby J; Green E
    J Am Med Dir Assoc; 2009 Feb; 10(2):115-9. PubMed ID: 19187879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic studies of atypical antipsychotic agents and diabetes.
    Postgrad Med; 2003 Dec; 114(6 Suppl Managing Metabolic):72-9. PubMed ID: 19667654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of antipsychotic medications on appetite, weight, and insulin resistance.
    Deng C
    Endocrinol Metab Clin North Am; 2013 Sep; 42(3):545-63. PubMed ID: 24011886
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serious cardiovascular events and mortality among patients with schizophrenia.
    Enger C; Weatherby L; Reynolds RF; Glasser DB; Walker AM
    J Nerv Ment Dis; 2004 Jan; 192(1):19-27. PubMed ID: 14718772
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia.
    Padmavati R; McCreadie RG; Tirupati S
    Schizophr Res; 2010 Aug; 121(1-3):199-202. PubMed ID: 20538429
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cross-sectional prevalence of metabolic syndrome in Korean patients with schizophrenia.
    Kang SH; Kim KH; Kang GY; Lee KH; Kim KK; Soh M; Ahn KJ; Kim SH; Lee JI
    Schizophr Res; 2011 May; 128(1-3):179-81. PubMed ID: 21303730
    [No Abstract]   [Full Text] [Related]  

  • 60. Longitudinal Trends in the Prevalence of Diabetes Mellitus in an Urban Emergency Department.
    Sterling SA; Jones AE; Cox RD
    South Med J; 2016 Apr; 109(4):222-7. PubMed ID: 27043803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.